Continuous subcutaneous @entity2690 infusion therapy and multiple daily XXXX injections in @entity6 : a comparative overview and future horizons.

@entity413 @entity2690 @entity2794 @entity6
INTRODUCTION: Continuous subcutaneous @entity2690 infusion (CSII) therapy is currently accepted as a treatment strategy for type 1 @entity6 . Transition from @entity2794 ( @entity2794 ; including basal-bolus regimens) to CSII is based on expectations of better metabolic control and fewer hypoglycaemic events. Evidence to date has not been always conclusive. Areas covered: Evidence for CSII and @entity2794 in terms of glycaemic control, hypoglycaemia and psychosocial outcomes is reviewed in the adult and paediatric population with type 1 @entity6 . Findings from studies on threshold-based @entity2690 pump suspension and predictive low @entity413 management (PLGM) are outlined. Limitations of current CSII application and future technological developments are discussed. Expert opinion: Glycaemic control and quality of life (QOL) may be improved by CSII compared to @entity2794 depending on baseline HbA1c and hypoglycaemia rates. Future studies are expected to provide evidence on clinical and cost effectiveness in those who will benefit the most. Training, structured education and support are important to benefit from CSII. Novel technological approaches linking continuous @entity413 monitoring (CGM) and CSII may help mitigate against frequent hypoglycaemia in those at risk. Development of @entity413 -responsive automated closed-loop @entity2690 delivery systems may reduce the burden of disease management and improve outcomes in type 1 @entity6 .
